New Novogen chief executive James Garner expects the company to start recruiting patients for trials of cancer drug Cantrixil by the end of 2016.
Dr Garner says he plans to review the drug developer's three most advanced programs, Cantrixil, Anisina and Trilexium, with the aim of getting each of them into the clinic as quickly as possible.
"I have sometimes seen initially promising molecules fail to live up to expectations. But I have also seen the enormous impact that successful products can have on the lives of patients and their families," Dr Garner said in a statement on Monday.
Dr Garner on Monday took over as chief executive from Ian Ross who's been acting in the role since founder Graham Kelly's resignation.
Share
